RSS   Newsletter   Contact   Advertise with us

Illumina to acquire Grail in deal worth $8bn

Christian Fernsby ▼ | September 22, 2020
Illumina has signed a definitive agreement to acquire multi cancer blood test developer Grail for cash and stock consideration of $8bn.
Grail   Illumina
The deal consists of $3.5bn in cash and $4.5bn in shares of Illumina common stock, subject to a collar. Additionally, Illumina will make future payments to Grail stockholders, representing a tiered single-digit percentage of certain Grail-related revenues.

Topics: Illumina Grail

Illumina currently owns 14.5% of Grail’s outstanding shares and approximately 12% on a fully diluted basis. Grail was established by Illumina in 2016 and became a spin-out later. The company specialises in the development of blood tests for the early detection of various cancer types.